Canada’s life sciences sector is facing a capital paradox. The country’s top 25-30 life sciences companies will need $1 billion over the next two years just to stay competitive, and that capital doesn’t exist domestically.
Enter BDC Capital’s answer: a new Life Sciences Fund launching in 2026, six years after spinning out Amplitude Ventures. Sources say the fund has allocated $100 million, and BDC is hiring a managing partner to build the strategy from scratch. The timing aligns with Budget 2025’s $1 billion Venture and Growth Capital Catalyst Initiative, which explicitly prioritizes life sciences alongside $656.9 million for dual-use technologies, including biodefence and life sciences applications. Together, these moves signal Canada’s intent to anchor more of the sector’s value chain domestically.
Where Capital Is Flowing in Life Sciences
The money isn’t spread evenly across the Canadian life sciences ecosystem. Here’s where investors are placing their bets:
Biotech: Mega-deals dominated, with Borealis Biosciences’ CA$248 million Series A accounting for 22% of all biotech funding. Investors sidestepped riskier early-stage ventures in favor of later-stage rounds.
Medical Devices: Saw a 30% increase, concentrated in large rounds like Kardium’s CA$143 million financing.
Digital Health: Took the most brutal hit, with 36% less funding in 2024 than in 2023. Behavioral and mental health platforms were the exception. Globally, digital therapeutics are projected to reach $70.4 billion by 2035 at a 26.7% CAGR.
Diagnostics: Remained the bright spot. Klick Labs’ Voice 2 Diabetes, which predicts Type 2 diabetes from a 10-second voice clip, exemplifies the AI-powered innovation gaining traction. The technology is being trained across multiple languages, accents, and ethnicities.
Femtech: Saw a 55% year-over-year funding increase, with Canada now hosting the world’s third-largest ecosystem in this space.
Canada's Regulatory Advantage
For international founders evaluating where to run clinical trials, Canada offers speed without compromising rigor:
- 30-day review timeline: Health Canada reviews Clinical Trial Applications within 30 days, compared to 60+ days in Europe and longer in the US.
- No IND requirement: Canada doesn’t require an IND for clinical trial approval, and Phase I data can be submitted directly to support FDA applications.
- Second-lowest G7 trial costs: Canada ranks second for affordability among G7 nations. Global pharma companies like Pfizer, Novartis, Roche, and Moderna (the first non-US facility in Laval) have all established Canadian operations.
- Strong trial infrastructure: Canada captures 4% of global clinical trials, ranking fourth in the number of sites.
Canada’s SR&ED program provides over $4 billion in investment tax credits annually. Budget 2025 expanded eligibility, making capital expenditures claimable for the first time.
How Drug Policy Shapes Commercialization
Canada’s pathway from regulatory approval to market access offers lessons that translate globally. After Health Canada approval, CADTH evaluates clinical and cost-effectiveness, streamlining market approval and reimbursement recommendations. The pan-Canadian Pharmaceutical Alliance then negotiates pricing on behalf of all provincial and federal drug plans, while the PMPRB ensures prices aren’t excessive compared to international benchmarks.
For international founders, successfully navigating Canada’s health technology assessment builds a playbook that applies to single-payer markets in Europe, Australia, and beyond. The economic modeling and value demonstrations required for Canadian market access mirror what’s needed in most developed healthcare systems outside the US, making it a strategic proving ground for drugs targeting chronic conditions, rare diseases, or precision medicine applications.
Why International Founders Choose Canada
For life sciences founders evaluating where to base clinical development, Canada’s value proposition is clear:
- Faster regulatory approvals at lower trial costs than most developed markets
- Diverse patient populations: 23% of Canadians are foreign-born, the highest in the G7
- Universal healthcare ensures exceptional participant health and high-quality trial data
- Robust infrastructure: 17 medical schools, 40 academic healthcare organizations, 15,000+ researchers
- Significant funding: CIHR allocates $1B+ annually to health research
Running trials in Canada’s single-payer system provides validation that mirrors healthcare models in Europe, Australia, and other developed markets. That real-world evidence travels when you’re pitching to investors or health systems outside the US.
The global life sciences industry recognizes this. AstraZeneca expanded its R&D operations in 2025, Roche invested $130+ million in its Mississauga hub, and AbbVie partnered with Toronto’s Ripple Therapeutics. These partnerships reflect growing recognition that Canada supports the entire life sciences development lifecycle.
The Path Forward
For international founders, the opportunity is concrete. Canada offers faster regulatory pathways, lower trial costs, and validation in a single-payer system that mirrors most developed markets outside the US. The infrastructure is proven, the talent is here, and with Budget 2025’s allocations, the capital is starting to catch up. If you’re building in biotech, diagnostics, or digital therapeutics and need a place to run trials or establish your first North American presence, put Canada at the top of your list.
TBDC works with life sciences and healthtech founders, connecting them with the mentorship, networks, and funding pathways that turn clinical validation into commercial traction. Learn more about our programs.
